Trial Search Results

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

The purpose of this study is to test the safety and maximum tolerated dose of RO6958688 with or without obinutuzumab pretreatment in patients with advanced solid tumors. In Part I (completed) 5 subjects received RO6958688. In Part II, the study will look at safety of RO6958688 either dosed weekly (QW) or every three weeks (Q3W). Pretreatment with obinutuzumab will also be tested in a subset of participants. Only subjects who test positive for CEA tumor expression (prescreening step) will be eligible to participate in the main study.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting